glp-1 news october 21 2025 trends 2025: real-world data, patient outcomes & future therapies A network meta-analysis backed weight-loss

Both human and animal studies reported inconsistent BP response to acute administration but showed hypotensive effect of chronic administration of GLP-1/ GLP-1 RAs

This is a year-over-year improvement of 30 percentage points, almost doubling after three years

Please confirm your status as a healthcare professional to access the content.

*All sales are FINAL, so please ensure you've selected the correct version before purchase

Aims/hypothesis Tirzepatide is a novel dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) currently under review for marketing approval